B.Riley FBR analyst Andrew D’silva maintained a Buy rating on Biomerica Inc (BMRA) on July 19 and set a price target of $6.25. The company’s shares closed on Friday at $2.98.
According to TipRanks.com, D’silva is a 4-star analyst with an average return of 7.0% and a 42.3% success rate. D’silva covers the Healthcare sector, focusing on stocks such as Cumberland Pharmaceuticals Inc, EyePoint Pharmaceuticals Inc, and Sensus Healthcare Inc.
Biomerica Inc has an analyst consensus of Moderate Buy, with a price target consensus of $6.25.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.95 and a one-year low of $1.60. Currently, Biomerica Inc has an average volume of 29.34K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. It focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests.
